Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality

Ge, Zhong; Qiao, Bing; Wang, Yanling; Zhang, Haifeng; Gou, Wei

doi:10.1097/md.0000000000021454

Cited by 7 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With antiviral treatments, the prognosis was comparable between patients with HBV loads <2000 IU/mL and those with HBV loads ≥2000 IU/mL after undergoing hepatectomy for early-stage HBV-related HCC. 24 For HCC patients receiving sorafenib, antiviral treatments could eliminate the adverse impacts of high HBV loads on survival. 25 Peter et al found that antiviral therapy can provide benefits for HCC patients in terms of survival, liver function and adverse events.…”

Section: Discussion/conclusionmentioning

confidence: 99%

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients

Hu¹,

Sun²,

Mei³

et al. 2022

JHC

View full text Add to dashboard Cite

Background In consideration of no standard exclusion criteria for hepatitis B virus (HBV) loads in hepatocellular carcinoma (HCC)-related clinical trials, this study aimed to investigate the prevalence of HBV-related exclusion criteria among current clinical trials and evaluate whether antiviral treatments could eliminate the adverse effects from high HBV loads for HCC patients. Methods This is a retrospective study including 772 HCC clinical trials on ClinicalTrials.gov and 1784 HCC patients receiving antiviral treatment. The Kaplan–Meier (K-M) method was used to compare the progression-free survival (PFS) and overall survival (OS) between different groups, and Cox regression analyses were performed to validate possible risk factors on PFS and overall survival OS. Results Among 772 clinical trials, 58.3% did not adopt baseline HBV loads as exclusion criteria, 18.0% was 2000 IU/mL, and 10.5% was receiving antiviral therapy. We observed baseline HBV loads had no significant impact on PFS (p = 0.491, 0.155, 0.119, 0.788, 0.280, 0.683 respectively) and OS (p = 0.478, 0.741, 0.263, 0.039, 0.999, 0.581 respectively) in all patients or each treatment group including hepatectomy, radiofrequency ablation, interventional therapy, targeted drugs and anti-programmed cell death immunotherapy, except for the OS of interventional therapy group, where patients with high HBV loads had higher BCLC stage, serum AFP level and ALBI grade (p = 0.009, 0.015 and 0.003, respectively). Conclusion Antiviral treatments could eliminate the adverse impacts of high HBV loads on the survival of HCC patients. Simplified eligibility criteria can be adopted for HCC patients with HBV infection where regular antiviral therapy should be enough.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients

Hu¹,

Sun²,

Mei³

et al. 2022

JHC

View full text Add to dashboard Cite

show abstract

“…A Chinese study of 233 patients with CHB-related compensated cirrhosis showed that TDF treatment led to significantly longer disease-free survival compared to ETV treatment after liver resection (33 months for TDF and 24 months for ETV, P <0.001) [ 26 ]. Another study from China also reported that TDF treatment was associated with a significantly lower rate of HCC recurrence (aHR, 0.67; 95% CIs, 0.48–0.93; P =0.04) after liver resection compared to non-TDF treatment, such as ETV [ 27 ].…”

Section: Tenofovir Is Better Than Entecavir For the Prevention Of Hccmentioning

confidence: 99%

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development. a Data are presented as mean ± standard deviation. 4060 (100) 6145 (100) 16.9 18.1 49 (0.61) 41 (0.32)

show abstract

“…Regarding the tertiary prevention of HCC after curative treatment, there are a few studies comparing the effectiveness of ETV and TDF in preventing HCC recurrence. A Chinese study including 233 patients with HBV-related HCC who underwent liver resections observed that TDF treatment was associated with a significantly longer disease-free survival compared with ETV (33 months vs. 24 months, respectively; P < 0.001) [21] . Another study from China including 479 patients with HBV-related HCC confirmed this finding that TDF treatment was superior to non-TDF treatment including ETV (aHR = 0.67; 95%CI: 0.48-0.93; P = 0.04) in preventing HCC recurrence after curative resection [22] .…”

Section: Studies Showing the Superiority Of Tdf In Tertiary Prevention Of Hccmentioning

confidence: 99%

Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B

Choi¹,

Choi²

2021

View full text Add to dashboard Cite

Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality

Abstract: Supplemental Digital Content is available in the text

Cited by 7 publications

References 35 publications

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B

Contact Info

Product

Resources

About